Company Updates
Aclarion (ACON) CFO John Lorbiecki to retire; search for successor begins
Aclarion, Inc. (Nasdaq: ACON) said on June 20, 2025 that chief financial officer John Lorbiecki will retire, and that it expects to name a successor before the end of the third quarter.

Aclarion, Inc. (Nasdaq: ACON) said in a Form 8-K filed on June 20, 2025 that its chief financial officer, John Lorbiecki, intends to retire. Lorbiecki told the company of the decision on June 16, 2025. The company said it had begun a search for his replacement and expected to appoint a new chief financial officer before the end of the third quarter of 2025.
Why is this important: A change in the finance chief at a company that reports its own cash and controls is a material event for shareholders, even when the departure is planned. The notice gives a timetable but no name. The company said the retirement did not result from any disagreement with it, and the filing gives no reason beyond that. For shareholders, the question is whether the transition holds the reporting process steady while the company keeps raising capital.
Brent Ness, the chief executive, is the company's chief operating decision maker in its financial statements. In our view, a planned exit is still a test. The search falls during a period when the company must keep its filings on time. We think the board should name the successor on the timetable it set, and explain how the handover will keep the numbers accurate.
What the notice says
The filing states that on June 16, 2025 Lorbiecki notified Aclarion, Inc. of his intention to retire from his position as chief financial officer. It says the company has initiated a search for his replacement. The company expects to appoint its new CFO before the end of the third quarter of 2025. The notice also says Lorbiecki will remain with the company over the next several months and will lead the effort to transition the CFO duties to his successor.
The filing says Lorbiecki, who is 62, joined the company as chief financial officer in October 2021, before the company's April 2022 initial public offering. It says his decision to retire did not result from any disagreement or difference of opinion with the company. The notice is filed under Item 5.02 of Form 8-K, which covers departures of principal officers.
The company's position in the spring of 2025
The quarterly report for the period ended March 31, 2025, filed on May 15, 2025, is the latest periodic report before the notice. It reports cash of $14,760,272 as of March 31, 2025. The report says the company raised capital during the quarter through two registered direct offerings and an underwritten public offering. The company describes its revenue as coming from Nociscan reports, which it delivers to clients for a fee.
The report names Brent Ness as chief executive and as the company's chief operating decision maker. It describes the company as operating in a single segment, Nociscan, and says revenue and cash flows come from fees for providing those reports.
The filings do not say why the company chose to search rather than appoint an interim finance head.
The first-quarter report shows a net loss of $2,037,436 for the three months ended March 31, 2025, against $2,399,102 a year earlier. Financing cash in the quarter included $14,554,545 from a public offering of common stock and warrants and $5,167,927 from registered direct offerings. Against that, the company paid $1,959,642 of issuance costs and $1,213,590 to redeem Series B preferred stock. The report says the reports sold by the company are not reimbursable under third-party payment arrangements, except for three private health insurance providers in the United Kingdom.
What comes next
The company's June 20 notice set one dated target, the end of the third quarter of 2025. The notice also says Lorbiecki stays on through the transition for several months. The filing does not say when the company expects to file its next quarterly report.
The notice is described in the Form 8-K filed June 20, 2025. The cash balance and the company's business are described in the Form 10-Q for the quarter ended March 31, 2025.
Investor Chat
Loading posts…
aibio